Tim Knotnerus

Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom.

Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria.

Ribometrix, Inc. develops small molecule drugs that target functional RNA structures to create new avenues to treat human disease. The company was founded by Kevin Weeks and Katie Warner and is headquartered in Greenville, NC.

Outrun Therapeutics Ltd. is a British biotechnology company founded in 2019 that develops a platform for drug discovery.

Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom.

Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom.

iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland.

Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands.

Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland.

Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland.

Redmile Group LLC (Redmile) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded by Jeremy Green and Michael Lee in 2007. Redmile provides investment management and advisory services to private investment funds and separately managed accounts.

Gilda's Club New York City, Inc. provides support services to cancer patients. Its programs include cancer support for all, offsite program, and programs for children and teens with cancer. The company was founded by Gene Wilder, Joanna Bull, Mandy Patinkin, and Joel Siegel in 1995 and is headquartered in New York, NY.

Precirix NV develops and distributes radio-immunotherapeutic drugs for cancer patients. The company was founded on October 14, 2014 by Jens De Vos, Ludwig Camusot, Nick Devoogdt, Geert Raes, Tony Lahoutte and Matthias Dhuyvetter and is headquartered in Brussels, Belgium.

DiogenX SAS engages in the discovery and development of biologics therapeutics options of Diabetic patients. It operates in Diabetes preclinical stage business segment. The company was founded by Benjamin Charles, Patrick Collombat and Jean Pascal Tranié on December 24, 2019 and is headquartered in Marseille, France.

Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts.

HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany.

Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany.

Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel.

TargEDys SA develops microbiome-based solutions for appetite regulation. It provides humanity with easy means of regulating their eating behaviors for the third millennium. The company was founded by Pierre Dechelotte and Gregory Lambert 2011 and is headquartered in Paris, France.

Pontifax Management Co. Ltd. (Pontifax) is a venture capital firm founded in 2004 by Eliyahu Hurvitz. The firm is headquartered in Herzliya Pituach, Israel.

Welch Capital Partners LLC (WCP) is an independent registered investment advisor and hedge fund manager headquartered in Brooklyn, New York. The firm was founded by Leighton Welch in 1996. WCP provides investment advisory services to separately managed accounts as well as a long-short private limited partnership.

SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands.

Phase2 Microtechnologies, Inc. is a technology development company that offers Micro-Electro-Mechanical Systems-enabled pH sensor technology platforms. The company was founded in 2016 and is headquartered in Pittsburgh, PA.

Fibriant BV is a Dutch biotechnology company that specializes in the recombinant manufacturing and characterization of specific variants of human Fibrinogen and active human Thrombin. The company is based in Leiden, the Netherlands. The company's science and technology are centered around Fibrinogen, a soluble blood protein that can be converted into an insoluble three-dimensional Fibrin network. Fibriant captures the unique features and functions of specific recombinant variants of Fibrinogen in new innovative products and in improvements of existing products based on plasma Fibrinogen. The company was founded in 2015 by Jaap Koopman, Jos Grimbergen, Miranda Weggeman, and Jaap Koopman has been the CEO since then.

Sense Biodetection Ltd. provides molecular diagnostics research services. It focuses on improving healthcare decisions and processes by developing novel, user-centred, handheld tests in the fields of infections and oncology. The company was founded by Harry John Lamble and Ralph Lamble in 2014 and is headquartered in Abingdon, the United Kingdom.

Earlybird Venture Capital GmbH & Co. KG (Earlybird VC) is an independent venture capital firm founded by Hendrik Brandis, Roland Manger, Rolf Mathies, and Christian Nagel in 1997. It is a wholly-owned subsidiary of Earlybird VC Management GmbH & Co. KG. The firm is headquartered in Munich, Germany, with another German office in Berlin, and international office in Istanbul, Turkey.

CEVEC Pharmaceuticals GmbH engages in the manufacture of biopharmaceuticals using a human cell-based expression system. It provides therapeutic proteins and monoclonal antibodies. The company was founded by Stefan Kochanek in 2004 and is headquartered in Cologne, Germany.

AYOXXA Biosystems GmbH operates as a biotechnology firm. Its lunaris technology is the optimal analysis platform for the pre-clinical and clinical development work. The firm offers In-situ encoded bead array, a multiplexed protein analysis platform that allows users to measure proteins and biomolecular analytes. The company was founded by Dieter Trau and Andreas Schmidt in 2010 and is headquartered in Cologne, Germany.

Part of CureVac NV, Frame Pharmaceuticals BV is a Dutch company that offers cancer therapy services. The company is based in Amsterdam, Netherlands. The company was founded by Ronald Plasterk, Bob Löwenberg. Ronald Plasterk has been the CEO since incorporation. Frame Pharmaceuticals was acquired by CureVac NV on June 08, 2022 for $34.26 million.

Impatients N.V. operates an online platform for drug innovations. It provides physicians and patients that are excluded from clinical trials access to drugs in development via early access programs. The company was founded by Ronald Brus, SJaak Vink, Govert J. Schouten, Witt Jan, Erdem Yavuz, and René Beukema in 2012 and is headquartered in Amsterdam, the United Kingdom.

Cryotherapeutics SA develops and markets a cryotherapy system, with focus on highlighting the safety and efficacy of cryoneergy in the cardiovascular system. The firm specializes in the design of a proprietary system to be used in the treatment of coronary artery diseases that cause heart attacks. Its focus areas encompass technology research, system development, and early-stage product commercialization. The company was founded by Randell L. Werneth, John Yianni and Maurice Buchbinder on September 8, 2009 and is headquartered in Cologne, Germany.